Anti-CD137 Monoclonal Antibody in Patients With Advanced Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 42
Summary
- Conditions
- Advanced Cancer
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentIntervention Model Description: Dose escalationMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This Phase 1 study will enroll up to approximately 86 evaluable adult subjects with refractory cancer (solid tumors) regardless of diagnosis. Subjects may be enrolled into the following cohorts: The trial will consist of a 3+3 dose escalation that will evaluate different combination dose levels of A...
This Phase 1 study will enroll up to approximately 86 evaluable adult subjects with refractory cancer (solid tumors) regardless of diagnosis. Subjects may be enrolled into the following cohorts: The trial will consist of a 3+3 dose escalation that will evaluate different combination dose levels of AGEN2373 monotherapy and in combination with Balstilimab (AGEN2034). Each subject will stay on the dose level at a schedule assigned at trial entry. Subjects can be replaced for any reason other than a DLT. Subjects will receive treatment for ? 2 years or until PD, unacceptable toxicity, or any criterion for stopping the study drug or withdrawal of trial occurs.
Tracking Information
- NCT #
- NCT04121676
- Collaborators
- Not Provided
- Investigators
- Study Director: Medical Director Agenus Inc.
Get Well Soon